ALHAMBRA, Calif., Sept. 27, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced the release of its inaugural Environmental, Social, and Governance ("ESG") At-a-Glance Report, which highlights the Company's achievements and ongoing initiatives in advancing health equity in the communities it serves while operating responsibly and sustainably.
Brandon Sim, Co-CEO of ApolloMed, stated, "ApolloMed was founded nearly 30 years ago based upon the belief that every individual deserves access to quality healthcare. We are very proud of the physician-centric, mission-driven organization that we have grown to become today, serving approximately 1.3 million members across all lines of business through a network of over 11,000 providers, as of June 30, 2023. We are pleased to share our ESG strategy and inaugural at-a-glance report, and we look forward to serving more and more local communities across the country by continuing to work closely with independent physicians and increasing equitable access to high-quality healthcare services. At the same time, we look forward to building upon our efforts to operate in a socially and environmentally responsible way."
Key highlights from the 2022 ESG At-a-Glance Report include:
To read the inaugural ESG report and learn more about ApolloMed, please visit: https://www.apollomed.net/investors/esg.
1 Data is based on analysis of percentage of all patients as of December 31, 2022. AAPI stands for Asian American and Pacific Islander.
2 Data is as of December 31, 2022, and includes information for Network Medical Management employees. Other underrepresented groups include individuals who are Black/African American, Asian/Pacific Islander, American Indian or Alaska Native, or who identify as Two or More Races, but are not Hispanic or Latino.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's operational focus and strategic growth plans. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the Securities and Exchange Commission ("SEC"), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2022, filed with the SEC and any subsequent quarterly reports on Form 10-Q.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
This email address is being protected from spambots. You need JavaScript enabled to view it.
Carolyne Sohn, The Equity Group
(408) 538-4577
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$31.38 |
Daily Change: | -1.32 -4.04 |
Daily Volume: | 340,654 |
Market Cap: | US$1.430B |
November 08, 2024 November 07, 2024 July 15, 2024 May 07, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load